Effects of ticagrelor on cardiorespiratory fitness in patients after percutaneous coronary intervention
10.3760/cma.j.issn.0253-3758.2020.02.004
- VernacularTitle: 替格瑞洛对冠状动脉介入治疗术后患者心肺适能的影响
- Author:
Chuan REN
1
;
Wei ZHAO
1
;
Tao SHEN
1
;
Xinye XU
1
;
Lequn ZHOU
1
;
Liyuan TAO
2
;
Wei GAO
1
Author Information
1. Department of Cardiology, Peking University Third Hospital, Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides of National Health Commission, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China
2. Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China
- Publication Type:Journal Article
- Keywords:
Coronary artery disease;
Percutaneous coronary intervention;
Ticagrelor;
Cardiorespiratory fitness
- From:
Chinese Journal of Cardiology
2020;48(2):104-110
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of ticagrelor on cardiorespiratory fitness in patients with coronary heart disease after percutaneous coronary intervention (PCI).
Methods:A total of 1 073 patients, who were diagnosed as coronary heart disease and underwent cardiopulmonary exercise testing (CPET) within 1 year after PCI, were enrolled from September 2017 to September 2019 in Peking University Third Hospital, including 309 patients in ticagrelor group and 764 patients in clopidogrel group. Clinical information, blood test results, echocardiographic parameters, cardiorespiratory fitness related parameters (including peak oxygen uptake (VO2), anaerobic threshold VO2, peak oxygen pulse (VO2/HR) and carbon dioxide ventilation equivalent (VE/VCO2) slope), coronary lesions and intervention information were obtained. Cardiopulmonary fitness related indexes were compared between the two groups, and the correlation between ticagrelor use and cardiopulmonary fitness related indexes was analyzed by multivariate logistic regression. Patients who underwent CPET within 1 month after PCI were included in the subgroup analysis.
Results:In ticagrelor group, the age was (60.3±10.3) years, and 253(81.9%) cases were male. The age of clopidogrel group was (60.6±10.0) years, and there were 608(79.6%) males. No significant differences were observed in peak VO2, anaerobic threshold VO2, and peak VO2/HR between the two groups (all P>0.05), but the VE/VCO2 slope was significantly higher in the ticagrelor group than in the clopidogrel group (30.075 (27.207, 33.603) vs. 28.853 (25.970, 32.336), P<0.001). Logistic regression analysis suggested that the peak VO2, anaerobic threshold VO2 and peak VO2/HR were not significantly correlated with the ticagrelor use (all P>0.05), while the VE/VCO2 slope was independently correlated with ticagrelor use (OR=1.098, 95%CI 1.032-1.168, P=0.003). Subgroup analysis of patients who underwent CPET within 1 month after PCI also indicated that no significant difference were observed in peak VO2, anaerobic threshold VO2, peak VO2/HR and VE/VCO2 slope between the two groups (all P>0.05). Logistic regression analysis suggested that the peak VO2, anaerobic threshold VO2 and peak VO2/HR were not significantly correlated with ticagrelor use (all P>0.05), while the VE/VCO2 slope was significantly correlated with ticagrelor use (OR=1.132, 95%CI 1.030-1.244, P=0.010).
Conclusion:Among coronary heart disease patients after PCI, treatment with clopidogrel does not result in significant decrease in exercise endurance as compared with patients treated with ticagrelor.
